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Abstract: The P-glycoprotein efflux system located on the apical membrane of brain capillary 
endothelial cells functions as part of the blood-brain barrier.  In this study, primary cultures of 
bovine brain microvessel endothelial cells (BMECs) were investigated for the presence of a P-
glycoprotein system and its contribution in regulating ivermectin distribution across the blood-
brain barrier.  Results of rhodamine 123 uptake studies with cyclosporin A and verapamil as 
substrates indicated that a functional efflux system was present on BMECs.  Immunoblot 
analysis with the C219 monoclonal antibody to the product of the multidrug resistant member 
1(MDR1) gene also confirmed the expression of MDR1 in the BMECs.  Unbound ivermectin was 
shown to significantly increase the uptake of rhodamine 123 in BMECs, however, the drug only 
modestly enhanced the transcellular passage of rhodamine.  The results of these studies 
affirmed that unbound ivermectin is an inhibitor of the MDR1 efflux system in BMECs. 
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INTRODUCTION 
 The failure of combination chemotherapy in the treatment of many cancers prompted 
research in the area of multidrug resistance which ultimately lead to the discovery of P-
glycoprotein, a 170-180 kDa glycoprotein associated with the plasma membrane of many drug 
resistant tumor cells.  P-glycoprotein is believed to function as an energy-dependent efflux 
pump and is often overexpressed in cancer cells (1).  P-glycoprotein is also expressed in 
noncancerous tissues including the endothelial cells of the blood-brain barrier (2-5).  
Specifically, the efflux system has been shown to be present and functional in the membranes 
of cultured murine (2,4), porcine (2), and bovine brain capillary endothelial cells (5).  The blood-
brain barrier has many unique characteristics which restrict the exchange of molecules 
between the systemic circulation and the extracellular fluid compartment of the brain.  These 
characteristics include the presence of tight intercellular junctions, the absence of fenestra, a 
reduced level of pinocytosis, and a complex glycocalyx.  The expression of the P-glycoprotein 
efflux system contributes an additional defense mechanism to the barrier (6). 
 Previously our laboratory investigated the uptake of ivermectin by bovine brain 
microvessel endothelial cells (BMECs) (7) and canine BMECs from ivermectin sensitive and 
ivermectin tolerant rough-coated collies (8).  Ivermectin is a complex macrocyclic lactone which 
possesses a broad spectrum of activity against several species of nematodes, arachnids, and 
insects that act as parasites.  Ivermectin, known for its relatively high potency and low toxicity, 
is commonly used for heartworm control in dogs as well as the treatment of various tropical 
diseases such as onchocerciasis or “river blindness” in humans (9).  Our previous studies with 
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BMECs concluded that ivermectin had only a limited affinity for the endothelial component of 
the normal blood-brain barrier (7). 
 Recent work has shown that “knockout” mice which were made deficient for the 
multidrug resistant member 1 (MDR1) gene are 100 times more sensitive to ivermectin than 
normal mice (10).  Ivermectin has significant retention and distribution in kidney, fat, and liver 
tissues but achieves its lowest tissue concentrations in the brain (11). Based on the “knockout” 
mice studies, it has been hypothesized that the P-glycoprotein system at the blood-brain barrier 
effluxes ivermectin, restricting ivermectin distribution into the brain (10).  The objective of this 
study was to demonstrate the expression and functional activity of MDR1 in primary cultures of 
bovine brain microvessel endothelial cells in our laboratory, and to demonstrate whether 
reduced ivermectin uptake by BMECs was due to the presence of MDR1.  Rhodamine 123, a 
known substrate for MDR1, was used as a fluorescent marker to assay for the functional activity 
of the efflux system (2,12-14). 
 
EXPERIMENTAL PROCEDURE 
 Materials.  Ivermectin (22,23-dihydroavermectin B1a) was donated by Merck & Co., 
Rahway, NJ.  Cyclosporin A, rhodamine 123, and verapamil were purchased from Sigma 
Chemical Company, St. Louis, MO.  All other compounds used were of the highest commercially 
available quality. 
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 Cell cultures. BMECs were isolated from gray matter of cerebral cortices by enzymatic 
digestion and subsequent centrifugation, and seeded into primary culture as detailed by Audus 
and Borchardt (15,16) and based on the original method by Bowman et al. (17).  This method 
has been extensively characterized (18,19).  Isolated BMECs were seeded at a density of 50,000 
cells/cm2 into 12- and 24-well plates, and 100 mm tissue culture dishes (Corning Costar 
Corporation, Cambridge, MA) that were pretreated with rat-tail collagen and bovine fibronectin 
(Sigma Chemical Co.).  The culture medium consisted of 45% minimum essential medium and 
45% F-12 Ham nutrient mixture (Gibco, Life Technologies, Grand Island, NY), 10 mM HEPES, pH 
7.4, 13 mM sodium bicarbonate, 10% plasma-derived equine serum, 100 µg/ml heparin, 100 
µg/ml streptomycin, 100 µg/ml penicillin G, 50 µg/ml polymyxin B, and 2.5 µg/ml amphotericin 
B (Sigma Chemical Co.).  The cells were cultured at 37°C with 95% humidity and 5% CO2.  The 
BMECs were fed on the third day after seeding and then every two days until a confluent 
monolayer was formed (10-14 days). 
 Human umbilical vein endothelial cells (HUVECs) were purchased from American Type 
Culture Collection and grown in T-flasks (25 cm2) according to supplier instructions.  Briefly, 
cells were thawed upon receipt, centrifuged, and resuspended at a concentration of 1.5 x 105 
cells/ml in culture medium (pH 7.4) containing 90% F-12 Ham nutrient mixture (Gibco), 10% 
fetal bovine serum (JRH Biosciences, Lenexa, KS), 1.176 mg/ml sodium bicarbonate, 100 µg/ml 
heparin, and 50 µg/ml endothelial cell growth supplement (Sigma Chemical Co.), pH 7.4.  Cells 
were maintained at 37°C with 95% humidity and 5% CO2 and were subcultured every 3-4 days 
at a split ratio of 1:2 to 1:3. 
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 Caco-2 cells were grown to differentiated monolayers in Transwell™ (Corning Costar) 
growth supports as detailed by Hidalgo et al. (20).   
 Rhodamine 123 uptake.  Primary cultures of BMECs were seeded into 12-well plates or 
24-well plates and grown to confluent monolayers.  The culture medium was aspirated from 
each well and 0.9 ml of various concentrations of cyclosporin A, ivermectin, and verapamil were 
added.  Cyclosporin A was first dissolved into 95% ethanol at a concentration of 1 mg/ml and 
then diluted with MEM, pH 7.4 (MEM, 50 mM HEPES, 100 µg/ml penicillin G, 100 µg/ml 
streptomycin, 50 µg/ml polymyxin B, and 2.5 µg/ml amphotericin B) to the desired 
concentrations.  Ivermectin was first dissolved in absolute methanol at a concentration of 1 
mg/ml and then diluted with MEM to the desired concentrations.   Control BMEC wells for 
cyclosporin A and ivermectin were exposed to equivalent amounts of diluted ethanol and 
methanol, respectively, as the drug-treated wells. Verapamil was dissolved in MEM, pH 7.4.  
The plates were incubated for specific times at 37°C.  After the incubation, 0.1 ml aliquots of 
rhodamine 123 were added to each well at a final concentration of 5 µM.  The plates were 
again incubated at 37°C for specific times.  After the second incubation period, the medium 
from each well was decanted off and the monolayers in each well were quickly rinsed three 
times with 0.01 M phosphate buffered saline (PBS), pH 7.4, 4°C.  The cell monolayers were 
solubilized by the addition of 1.0 ml of 0.2N NaOH / 0.5% Triton X-100.  The contents of each 
well were collected into cuvettes and assayed by fluorescence using a SLM-Aminco 4800 
fluorometer (ex = 500 nm, em = 550 nm).  After reading the fluorescence, 100 µl was removed 
from each cuvette and analyzed for protein content with the BCA protein assay kit (Pierce, 
Rockford, IL). 
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HUVECs were grown to confluence in T-flasks (25 cm2).  The culture medium was 
removed from the flasks and the cells were rinsed two times with PBSA, 37°C, pH 7.4 (129 mM 
NaCl, 2.5 mM KCl, 7.4 mM Na2HPO4, 1.3 mM KH2PO4, 0.63 mM CaCl2, 0.74 mM MgSO4, 0.1 mM 
ascorbic acid, and 5.3 mM glucose).  The cells were then exposed to 5 ml of PBSA containing 5 
µM rhodamine 123 for controls, or 5 µM rhodamine 123 plus 100 µM cyclosporin A or 
verapamil.  The HUVECs were incubated under these conditions at 37°C for 30 minutes at which 
time the rhodamine 123 solutions were removed and the cells were rinsed twice with 0.01 M 
PBS, 4°C.  The monolayers were solubilized by the addition of 0.2N NaOH / 0.5% Triton X-100 
and assayed by fluorescence.  The results were normalized for protein content using a BCA 
protein assay kit (Pierce). 
P-glycoprotein immunoblot.  Total cellular extract was prepared using confluent 
monolayers of Caco-2 cells and BMECs.  The cells were lysed via 45 min incubation in ice-cold 
phosphate buffer saline (PBS) containing 3% sodium dodecyl sulfate (SDS) and protease 
inhibitors (0.1 mM leupeptin, 73 µM pepstatin A, and 100 µg/ml PMSF).  The cell lysate was 
then centrifuged at 12,000 x g for 15 min and the supernatant containing solubilized membrane 
proteins was stored at -20°C and used for further analysis.  Total cell protein was measured by 
the Micro BCA protein assay (Pierce, Rockford, IL) using bovine serum albumin as a standard.  
Cell proteins were electrophoresed on a 10% Tris-Glycine gel (NOVEX, San Diego, CA) and 
transferred to a PVDF membrane.  Immunoreactive protein was detected with the C219 
monoclonal antibody (Signet, Deadham, MA) using the enhanced chemiluminescence method 
(ECL) as per the manufacturer’s protocol (Amersham, Downers Grove, IL).  Caco-2 cell lysate 
was used as a positive control (21). 
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Transendothelial permeability studies in BMECs.  Polycarbonate membranes (pore size 
3.0 µm) were placed into 100 mm tissue culture dishes and coated with rat-tail collagen and 
bovine fibronectin.  Brain microvessel endothelial cells (BMECs) were grown to confluent 
monolayers, as determined by inspection of the areas around the membranes using an inverted 
microscope.  The basolateral side of the cells was defined as the side facing the collagen matrix 
(16,19).  Once confluence was attained, the membranes were rinsed with MEM, pH 7.4 and 
placed in a horizontal Side-bi-Side diffusion cell apparatus (Crown Glass, Inc., Somerville, NJ) 
for transendothelial permeability studies.  The area of the diffusion membrane was 0.636 cm2.  
The donor and receiver chambers were filled with 3.0 ml of MEM, pH 7.4 and the temperature 
was maintained with an external circulating water bath.  The contents of each chamber were 
stirred with Teflon coated magnetic stir bars at a speed of 600 r/min driven by an external drive 
console (Crown Glass, Inc.).  Rhodamine 123 was dissolved in PBSA and diluted to a final 
concentration of 5 µM in the donor chamber.  The transendothelial permeability of rhodamine 
123 alone was followed for 30 minutes.  Several 100 µl samples were taken from the receiver 
chamber during this time.  After each sample, the volume was replaced with fresh MEM.  After 
monitoring rhodamine 123 transport for 30 minutes, ivermectin (250 ng/ml or 1 µg/ml) 
dissolved in 5 µM rhodamine 123 was added to the diffusion cell donor chambers.  Transport 
was followed for an additional 90 minutes with 100 µl samples taken every 15 minutes from the 
receiver chamber.  Permeability was followed in the presence and absence of serum.  All 
samples were placed into cuvettes and diluted to 1 ml with PBSA.  Fluorescence was assayed 
with a SLM-Aminco 4800 fluorometer (ex = 500 nm, em = 500 nm).  The flux was determined by 
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plotting pmoles vs. minutes.  The apparent permeability coefficient was calculated using the 
equation: 
   P = Flux / (A*CDo)      
where flux is the slope of the line, A is the area of the membrane, and CDo is the initial donor 
concentration (19). 
Statistical analysis.  The comparison between mean values within each experimental 
series was performed by one-way analysis of variance using Dunnett’s test to compare several 
treatments against a control. 
 
RESULTS 
 Rhodamine 123 uptake experiments. Rhodamine 123 is a fluorescent dye commonly 
used for the determination of P-glycoprotein function in vivo and in vitro (2,12-14).  Cyclosporin 
A is a known substrate for the P-glycoprotein efflux system in vivo and in vitro (3,5,14).  In 
Figure 1 the effect of cyclosporin A on rhodamine 123 uptake in BMECs is shown.  All 
concentrations of cyclosporin A used in this study produced a significant increase in the uptake 
of rhodamine 123 by BMECs.  Figure 2 shows the concentration-dependent effect of verapamil 
on rhodamine 123 uptake in BMECs where the higher concentrations of verapamil significantly 
increased the uptake of the fluorescent marker.  Verapamil is also a known substrate for the P-
glycoprotein system; however, cyclosporin A was shown to have a greater effect on the efflux 
system in brain capillaries than verapamil (3). 
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To further establish that the functional activity measured with rhodamine 123 was due 
to efflux by MDR1, we examined uptake of the fluorescent marker in HUVECs, which do not 
express P-glycoprotein (2,4) as a negative control.  The results of incubating HUVECs in 5 µM 
rhodamine 123 and100µM cyclosporin A or 100µM verapamil are illustrated in Figure 3.  
Neither cyclosporin A nor verapamil were shown to have a significant effect on HUVEC uptake 
of rhodamine 123 at the concentrations studied. 
 P-glycoprotein immunoblot.  The expression of P-glycoprotein in BMEC lysate was 
determined with anti-MDR1 monoclonal antibody C219 using the ECL method.  Figure 4 shows 
a representative band in both BMEC and Caco-2 cell lysate at ~170 kDa.  Caco-2 cells were 
shown to express P-glycoprotein (21) and were used in this experiment as a positive control.    
Similar blots using the nonspecific mouse IgG revealed no immunoreactivity (not shown).  
 Ivermectin effects on rhodamine 123 uptake in BMECs.  The uptake of rhodamine 123 in 
BMECs was studied alone and after a one hour preincubation with ivermectin.  After the 
preincubation period, the cells were incubated one hour with rhodamine 123.  In Figure 5, the 
typical concentration-dependent effect of ivermectin on rhodamine 123 uptake by BMECs is 
illustrated in the absence of serum. The higher concentrations (25 ng/ml or greater) of 
ivermectin were found to significantly increase the uptake of rhodamine 123 in BMECs.  Figure 
6A shows the effect of cyclosporin A, a known P-glycoprotein inhibitor, compared with selected 
concentrations of ivermectin on rhodamine 123 uptake in BMECs with medium without serum. 
The uptake of rhodamine 123 in BMECs with cyclosporin A and ivermectin was also studied with 
medium containing 10% equine serum and  Figure 6B shows that cyclosporin A still inhibited 
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rhodamine 123; however, ivermectin’s effects were completely inhibited in the presence of 
serum.   
 Transendothelial permeability studies in BMECs.  The effects of BMEC monolayer 
pretreatment and subsequent exposure to ivermectin on rhodamine 123 transport through the 
BMEC monolayers was determined.  Transendothelial permeability studies were performed in 
medium and medium containing 10% equine serum.  A sample of the results obtained are 
illustrated in Figure 7.  Ivermectin at 250 ng/ml reproducibly increased the transmonolayer 
permeability of rhodamine 123 in medium that did not contain serum although this increase 
was not statistically significant.  Concentrations nearer reported circulating levels of ivermectin 
(≈10-100 ng/ml) had no effect on the permeation of rhodamine 123 across the BMEC 
monolayers.  By contrast, there was no increase on rhodamine 123 permeability observed with 
1µg/ml ivermectin treatment when the medium contained serum. 
  
DISCUSSION 
 The first part of this study confirmed the functionality and specific expression of P-
glycoprotein in primary cultures of BMECs in our laboratory.  Both cyclosporin A and verapamil 
were shown to increase the uptake of rhodamine 123, a fluorescent marker of the P-
glycoprotein efflux system (2,12-14).  Cyclosporin A and verapamil are known inhibitors of the 
P-glycoprotein efflux system that are commonly used to distinguish the existence of this efflux 
system on cells (2,3,5,13,14).  Our results compare favorably, in a qualitative manner, with the 
studies of Wang et al. (14) who showed about a 3-fold enhancement of rhodamine 123 uptake 
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in rat brain in the presence of cyclosporin A.   Enhancement of rhodamine 123 uptake in the 
presence of verapamil was also consistent with the ability of calcium influx blockers to 
modulate drug efflux by MDR1 positive cells (2,13,22).  The lack of effect of cyclosporin A or 
verapamil on rhodamine 123 uptake in HUVECs, cells negative for MDR1 (2,4), further 
supported the use of rhodamine 123 as a specific marker to evaluate the role of MDR1 efflux in 
BMECs in this study.  Finally, the existence of a BMEC P-glycoprotein was further evidenced by 
the results of immunoblots which affirmed expression of an immunoreactive protein with the 
C219 monoclonal antibody, previously shown to be specific for MDR1 expression (10).  
 Despite being relatively lipophilic, ivermectin typically achieves its lowest concentrations 
in the brain (11).   Supporting that observation was our previous work which demonstrated that 
the uptake of ivermectin by bovine BMECs was a limited process and subject to further 
restrictions in the presence of serum (7). Until recently, however, an exception existed in that 
certain rough-coated collies, exhibit higher brain concentrations of ivermectin compared with 
“normal” rough-coated collies (23).  One can also distinguish between ivermectin sensitive and 
ivermectin tolerant collies on the basis of a greater verapamil-sensitive uptake of the drug by 
primary cultures of BMECs isolated from the ivermectin-sensitive collies (8).  Schinkel et al.’s 
(10) work subsequently showed that in mice deficient in MDR1a, high levels of ivermectin 
accumulate in the brain, implicating a significant role for blood-brain barrier P-glycoprotein in 
regulating ivermectin distribution into the brain. 
  Our results provided further evidence that unbound ivermectin is at least an inhibitor of  
MDR1.  We observed a significant increase in rhodamine 123 uptake when BMECs were 
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preincubated for one hour with 50 and 500 ng/ml ivermectin. Therefore, increased rhodamine 
123 accumulation by BMECs occurred with treatments within the 10-100 ng/ml drug 
concentration range coinciding with the normal circulating  levels of ivermectin (24,25).  The 
ivermectin-induced increase in rhodamine 123 uptake was comparable to the increase seen 
with cyclosporin A and expected since these two drugs have similar apparent affinities for the 
MDR1 efflux system of other cell types (26).  By contrast, in the presence of 10% serum in the 
medium, the highly protein bound ivermectin did not alter the uptake of rhodamine 123 by 
BMECs whereas the effect of cyclosporin A on rhodamine 123 uptake was still significant.  This 
is an interesting observation since cyclosporin A is both highly protein bound and effectively 
trapped by brain endothelia (27).  This observation was consistent with work in myeloma cell 
lines where Lehnert et al. (28) demonstrated that cyclosporin A concentrations above those 
achievable in humans effectively inhibited MDR1 even in the presence of serum.   However, 
Lehnert et al. also observed that the actions other MDR1 inhibitors, amiodarone and 
trifluorperazine, were extremely sensitive over wide concentration ranges to the presence of 
serum (28).  The uptake and entrapment of ivermectin by BMECs in the presence of serum (7), 
is at least 100-fold lower than the reported entrapment of cyclosporin A (27) and therefore, 
differences in inhibition of rhodamine 123 uptake by ivermectin and cyclosporin A in the 
presence of serum may reflect a combination of factors including differential protein binding 
and BMEC affinity for the two drugs.   As pointed out by other researchers (28), the presence of 
serum in vivo and in vitro is an important variable in characterizing the inhibitory activity of 
some agents towards MDR1. 
Rose, J.M., Peckham, S.L., Scism, J.L., and Audus, K.L. (1998)  Evaluation of the role of P-glycoprotein in ivermectin uptake by 
primary cultures of bovine brain microvessel endothelial cells. Neurochem. Res. 23, 203-209.  PMID: 9475515.  Publisher’s 
official version: <http://dx.doi.org/10.1023/A:1022485026198> .  Open Access version:  http://kuscholarworks.ku.edu/dspace/. 
14 
 
In an earlier study, we demonstrated that permeation of 30 ng/ml of 3H-ivermectin 
across bovine BMEC monolayers was not altered by 10 µg/ml unlabeled ivermectin (7).  The 
MDR1 efflux system would have been implicated as the sole regulator of ivermectin passage 
across bovine BMECs had the substantial excess of unlabeled ivermectin enhanced permeation 
of the labeled form of the drug. In fact, the effect of apparent P-glycoprotein inhibition on the 
ehanced permeation of drugs across bovine BMECs has been recently demonstrated in our 
laboratory for other drugs (29).  Although high concentrations of ivermectin enhanced the 
permeation of the MDR1 substrate, rhodamine 123, across BMEC monolayers reproducibly, the 
effect was not statistically significant.  Serum protein in the medium again did block the modest 
enhancing effect of ivermectin on rhodamine 123 permeation across the BMEC monolayers.  
These in vitro studies are short term relative to in vivo studies where drug distribution into the 
brain tissue and neurotoxicity is examined over a period of partial days to weeks (10,26).  Thus, 
despite only a modest effect of ivermectin on the rhodamine permeation rate, over time one 
could expect greater accumulation of the marker on the brain tissue side of BMECs when 
MDR1 is inhibited.    
 Clearly, not all drugs have the same affinity for MDR1, MDR1 systems do vary somewhat 
among species (10,26), and there are some indications that MDR1 may vary in localization at 
the blood-brain barrier, particularly in the human, where there is conflicting evidence of MDR1 
localization from the typical luminal membrane (30) to an abluminal and astrocyte location 
(31).  Consequently, explanations for our observations of the only modestly enhanced 
rhodamine 123 diffusion across the BMECs in the presence of ivermectin may also include the 
possibility that the drug does inhibit the MDR1 on the apical membrane, but additional factors, 
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including other transport systems or binding sites in the cell control rhodamine123 transfer 
across bovine BMECs.  
 In summary, we conclude that there is an MDR1 efflux system associated with primary 
cultures of bovine BMECs and that unbound ivermectin is an inhibitor for this efflux system.  
This observation provides further support for the contributions of the MDR1 efflux system in 
the neurotoxicity of ivermectin and other drugs associated with some species of animals. 
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FIGURE LEGENDS 
Figure 1.  Percentage of rhodamine 123 (initial concentration 5 µM) uptake in bovine brain 
microvessel endothelial cells alone (shaded bar) and in the presence of cyclosporin A (hatched 
bar) for 60 minutes at 37°C, pH 7.4.  Each bar represents the mean ± SD of n = 6.  ** represents 
statistically significant changes (P < 0.01). 
 
Figure 2.  Percentage of rhodamine 123 (initial concentration 5 µM) uptake in bovine brain 
microvessel endothelial cells alone (shaded bar) and in the presence of verapamil (hatched bar) 
for 40 minutes at 37°C, pH 7.4.  Each bar represents the mean ± SD of n = 5.  ** represents 
statistically significant changes (P < 0.01). 
 
Figure 3.  Rhodamine 123 (initial concentration 5 µM) uptake in human umbilical vein 
endothelial cells alone (shaded bar) and in the presence of 100 µM cyclosporin A or verapamil 
(hatched bars) for 30 minutes at 37°C, pH 7.4.  Each bar represents the mean ± SD of n = 3. 
 
Figure 4.  Immunoblot analysis of P-glycoprotein (170 kDa) expression in BMEC and Caco-2 cell 
monolayers. 
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Figure 5.  Concentration dependent effect of ivermectin on rhodamine 123 (initial 
concentration 5 µM) uptake by bovine brain microvessel endothelial cells at 60 minutes at 37°C.   
Each point is the mean  ±  SD for n = 4. ** represents statistically significant changes (P < 0.01).   
 
Figure 6. A) Rhodamine 123 (initial concentration 5 µM) uptake by bovine brain microvessel 
endothelial cells alone (shaded bar) and after a one hour preincubation with 1 µg/ml 
cyclosporin A or selected concentrations of ivermectin (hatched bars) for 60 minutes at 37°C.  
Each bar represents the mean ± SD of n = 4.  ** represents statistically significant changes (P < 
0.01).  B) Rhodamine 123 (initial concentration 5 µM) uptake in bovine brain microvessel 
endothelial cells alone (shaded bar) and after a one hour preincubation with 1 µg/ml 
cyclosporin A or different concentrations of ivermectin (hatched bars) in medium containing 
10% equine serum for 60 minutes at 37°C.  Each bar represents the mean ± SD of n = 4.  ** 
represents statistically significant changes (P < 0.01). 
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Figure 7.  Apparent permeability of rhodamine 123 alone (Rhod; shaded bars) and in the 
presence of ivermectin (Iver; hatched bars).  Rhod* and Iver* represent apparent permeability 
of rhodamine 123 with 10% equine serum added to the medium.  Each bar represents the 
mean ± SD of n = 3. 
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